Stockreport

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst [Seeking Alpha]

Palvella Therapeutics, Inc.  (PVLA) 
PDF Palvella's QTORIN rapamycin platform demonstrates high local efficacy with minimal systemic exposure, validated across multiple rare skin disease indications. With $6 [Read more]